AT-GTX-502

DB17001ExperimentalGene Therapies

AT-GTX-502 is an experimental, one-time gene therapy that uses AAV9 to deliver a functional copy of CLN3.

Code names
AT-GTX-502

Which companies are running trials of AT-GTX-502, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In